BMRN

BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results

[GlobeNewswire] – Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM(TM) Underway; Positive CHMP Opinion Received February 20 moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

BioMarin to Present at the Cowen Healthcare Conference in Boston

[GlobeNewswire] – SAN RAFAEL, Calif. — BioMarin Pharmaceutical Inc. , a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Maher, Senior Vice President, … moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome

[GlobeNewswire] – SAN RAFAEL, Calif. — BioMarin Pharmaceutical Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for … moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]